MCID: RBL001
MIFTS: 53

Rubella

Categories: Rare diseases, Infectious diseases, Fetal diseases, Neuronal diseases

Aliases & Classifications for Rubella

Summaries for Rubella

MedlinePlus : 41 rubella is an infection caused by a virus. it is usually mild with fever and a rash. about half of the people who get rubella do not have symptoms. if you do get them, symptoms may include a rash that starts on the face and spreads to the body mild fever aching joints, especially in young women swollen glands rubella is most dangerous for a pregnant woman's baby. it can cause miscarriage or birth defects. rubella spreads when an infected person coughs or sneezes. people without symptoms can still spread it. there is no treatment, but the measles-mumps-rubella (mmr) vaccine can prevent it. centers for disease control and prevention

MalaCards based summary : Rubella, also known as german measles, is related to chickenpox and aseptic meningitis, and has symptoms including exanthema, fever and pruritus. An important gene associated with Rubella is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and PI3K-Akt signaling pathway. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and brain.

Disease Ontology : 12 A viral infectious disease that results_in infection located in skin, has material basis in Rubella virus, which is transmitted_by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted_by congenital method. The infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC : 3 Rubella is a contagious disease caused by a virus. Most people who get rubella usually have a mild illness, with symptoms that can include a low-grade fever, sore throat, and a rash that starts on the face and spreads to the rest of the body. Rubella can cause a miscarriage or serious birth defects in a developing baby if a woman is infected while she is pregnant. The best protection against rubella is MMR (measles-mumps-rubella) vaccine.

Wikipedia : 72 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

Diseases in the Rubella family:

Congenital Rubella

Diseases related to Rubella via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
id Related Disease Score Top Affiliating Genes
1 chickenpox 29.9 CD40LG HLA-B TNF
2 aseptic meningitis 29.7 HLA-A HLA-B HLA-DRB1 TNF
3 status epilepticus 29.4 IL4 MOG TNF
4 asthma 28.6 CD40LG HLA-DPB1 HLA-DRB1 IL4 TNF
5 congenital rubella 12.5
6 rubella panencephalitis 11.9
7 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 11.8
8 measles 11.4
9 mumps 11.3
10 acute disseminated encephalomyelitis 11.2
11 congenital toxoplasmosis 11.0
12 cytomegalic inclusion disease 11.0
13 microcephaly 10.9
14 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 10.7
15 immunodeficiency 45 10.7
16 acute hemorrhagic leukoencephalitis 10.7
17 congenital intrauterine infection-like syndrome 10.7
18 togaviridae disease 10.7
19 immune-mediated encephalomyelitis 10.7
20 postinfectious encephalomyelitis 10.7
21 anthracosilicosis 10.6 HLA-DPB1 HLA-DRB1
22 autosomal recessive severe congenital neutropenia due to cxcr2 deficiency 10.5 HLA-A HLA-B
23 rickettsialpox 10.5 CD40LG TNF
24 idiopathic subglottic tracheal stenosis 10.5 HLA-B HLA-DRB1
25 lung disease 10.5 CD40LG TNF
26 plasmodium falciparum malaria 10.5 CD40LG HLA-B
27 submandibular gland disease 10.5 CD40LG TNF
28 cardioskeletal syndrome, kuwaiti type 10.5 HLA-A HLA-B
29 lens-induced iridocyclitis 10.5 HLA-A HLA-B
30 diabetic angiopathy 10.4 CD40LG IL4
31 newborn respiratory distress syndrome 10.4 HLA-DPB1 HLA-DRB1 MOG
32 cellular schwannoma 10.4 CD40LG MOG TNF
33 autoimmune retinopathy 10.4 HLA-DRB1 TNF
34 infectious anterior uveitis 10.4 CD40LG HLA-B HLA-DPB1
35 epstein-barr virus hepatitis 10.4 HLA-DRB1 TNF
36 tracheal stenosis 10.4 HLA-DPB1 MOG TNF
37 acute ackee fruit intoxication 10.4 IL4 TNF
38 anencephaly and spina bifida x-linked 10.3 HLA-DRB1 TNF
39 pulmonary hemosiderosis 10.3 HLA-DRB1 MOG TNF
40 aniseikonia 10.3 CD40LG IL4
41 central nervous system leiomyosarcoma 10.3 CD40LG HLA-DRB1 TNF
42 causalgia 10.3 CD40LG MOG TNF
43 hepadnavirus infection 10.3 CD40LG HLA-DRB1 TNF
44 basidiobolomycosis 10.3 IL4 TNF
45 polyneuropathy due to drug 10.3 CD40LG IL4
46 lagophthalmos 10.3 IL4 TNF
47 plummer's disease 10.3 CD40LG HLA-DRB1 TNF
48 endogenous depression 10.3 CD40LG HLA-DRB1 TNF
49 biemond syndrome 10.3 HLA-DPB1 HLA-DRB1 TNF
50 cutaneous ganglioneuroma 10.3 CD40LG IL4

Graphical network of the top 20 diseases related to Rubella:



Diseases related to Rubella

Symptoms & Phenotypes for Rubella

UMLS symptoms related to Rubella:


exanthema, fever, pruritus

Drugs & Therapeutics for Rubella

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
2 Antibodies Phase 4,Phase 2,Phase 1
3 Immunoglobulins Phase 4,Phase 2,Phase 1
4 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
5 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4
7
Aluminum hydroxide Approved Phase 3,Phase 2 21645-51-2
8
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
9
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
10
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
11 PENTA Phase 3,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 2
13 Anti-Infective Agents Phase 3,Phase 2
14 Protective Agents Phase 3,Phase 2
15 Antioxidants Phase 3
16 Micronutrients Phase 3
17 Retinol palmitate Phase 3
18 Trace Elements Phase 3
19 Vitamins Phase 3
20 retinol Nutraceutical Phase 3
21
Altretamine Approved Phase 2 645-05-6 2123
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3
23
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
24
Lomustine Approved Phase 2 13010-47-4 3950
25
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
26
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
27
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
28
Mycophenolic acid Approved Phase 2 24280-93-1 446541
29
Obinutuzumab Approved Phase 2,Phase 1 949142-50-1
30
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
31
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
32 Anticoagulants Phase 2
33 Fibrinolytic Agents Phase 2
34 Alkylating Agents Phase 2
35 Angiogenesis Inhibitors Phase 2
36 Angiogenesis Modulating Agents Phase 2
37 Antibiotics, Antitubercular Phase 2
38 Antiemetics Phase 2
39 Anti-Inflammatory Agents Phase 2
40 Antineoplastic Agents, Hormonal Phase 2
41 Autonomic Agents Phase 2
42 Gastrointestinal Agents Phase 2
43 glucocorticoids Phase 2
44 Hormone Antagonists Phase 2
45 Hormones Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
47 Immunosuppressive Agents Phase 2
48 Methylprednisolone acetate Phase 2
49 Methylprednisolone Hemisuccinate Phase 2
50 Neuroprotective Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 139)

id Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Coadministration of Measles-rubella and Rotavirus Vaccines Completed NCT01700621 Phase 4
3 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
4 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
5 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
6 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
7 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
8 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
9 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
10 Measles, Mumps, and Rubella (MMR) Immunity in College Students Completed NCT00962819 Phase 4
11 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
12 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
13 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
14 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
15 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
16 MMR and Varicella Vaccine in Premature Infants Completed NCT00156559 Phase 4
17 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
18 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
19 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
20 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
21 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
22 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Active, not recruiting NCT02325310 Phase 4
23 The Phase IVd of Inactivated Enterovirus 71 Vaccine Enrolling by invitation NCT03296410 Phase 4
24 Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age Not yet recruiting NCT03071575 Phase 4
25 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Not yet recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
26 Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines Terminated NCT00138255 Phase 4
27 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
28 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
29 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
30 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
31 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
32 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
33 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
34 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
35 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
36 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
37 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
38 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
39 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
40 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
41 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
42 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
43 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
44 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
45 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
46 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
47 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
48 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly Completed NCT00432042 Phase 3
49 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
50 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3

Search NIH Clinical Center for Rubella

Cochrane evidence based reviews: rubella

Genetic Tests for Rubella

Anatomical Context for Rubella

MalaCards organs/tissues related to Rubella:

39
Skin, Eye, Brain, Heart, Testes, Lymph Node, Liver

Publications for Rubella

Articles related to Rubella:

(show top 50) (show all 1275)
id Title Authors Year
1
Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. ( 28231366 )
2017
2
Can Norway be kept free from rubella and measles? ( 28828847 )
2017
3
Rubella, herpes simplex virus type 2 and preeclampsia. ( 28747200 )
2017
4
Adult Rubella in a Returned Traveler. ( 28768990 )
2017
5
The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014. ( 28850604 )
2017
6
An update on epidemiology of congenital rubella syndrome: how far from the World Health Organization goals? ( 28728344 )
2017
7
Sociodemographic and economic characteristics of susceptibility to rubella among women preparing for pregnancy in rural China. ( 28739423 )
2017
8
Transitioning Lessons Learned and Assets of the Global Polio Eradication Initiative to Global and Regional Measles and Rubella Elimination. ( 28838195 )
2017
9
50 Years Ago in The Journal of Pediatrics: Cerebral Lesions in Congenital Rubella Syndrome. ( 28129869 )
2017
10
Expansion of Surveillance for Vaccine-preventable Diseases: Building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network Platforms. ( 28838191 )
2017
11
Pain caused by measles, mumps, and rubella vaccines: A systematic literature review. ( 28893478 )
2017
12
Complete Genome Sequence of a Genotype 2B Rubella Virus Isolated in South Korea in 2015. ( 28935733 )
2017
13
Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. ( 28855159 )
2017
14
The end of measles and congenital rubella: an achievable dream? ( 28067934 )
2017
15
Measles, Rubella and Varicella IgG Seroprevalence in a Large Refugee Cohort in Germany in 2015: A Cross-Sectional Study. ( 28875465 )
2017
16
Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. ( 28806450 )
2017
17
Analysis of VSV pseudotype virus infection mediated by rubella virus envelope proteins. ( 28912595 )
2017
18
Prevalence of Rubella Antibodies Among Children in the Democratic Republic of the Congo. ( 28746265 )
2017
19
Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies. ( 27810866 )
2017
20
Mumps, Measles, and Rubella Vaccine for the Treatment of a Recalcitrant Subungual Wart. ( 28709617 )
2017
21
Utilization and impact of European immunization week to increase measles, mumps, rubella vaccine uptake in Austria in 2016. ( 28797728 )
2017
22
Two Imported Cases of Congenital Rubella Syndrome and Infection-Control Challenges in New York State, 2013-2015. ( 28510706 )
2017
23
Susceptibility of Rubella Among Pregnant Women Attending the Antenatal Clinic in a Tertiary Care Hospital, Jabalpur, Central India. ( 27925863 )
2017
24
Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal. ( 28838201 )
2017
25
FUNDUS AUTOFLUORESCENCE IN RUBELLA RETINOPATHY: Correlation With Photoreceptor Structure and Function. ( 28005720 )
2017
26
Hospital-based surveillance of congenital rubella syndrome in Indonesia. ( 28091778 )
2017
27
Sensory defects and developmental delay among children with congenital rubella syndrome. ( 28406248 )
2017
28
Impact of the two-dose rubella vaccination regimen on incidence of rubella seronegativity in gravidae aged 25 years and younger. ( 28854204 )
2017
29
Molecular Epidemiology of Rubella Virus Strains Detected Around the Time of the 2012-2013 Epidemic in Japan. ( 28848523 )
2017
30
Underreporting of congenital rubella in Italy, 2010-2014. ( 28551878 )
2017
31
Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )
2017
32
Congenital rubella syndrome: an unusual cause of neonatal fulminant hepatic failure. ( 28678001 )
2017
33
Clinically Confirmed Congenital Rubella Syndrome: The Role of Echocardiography. ( 28579716 )
2017
34
Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. ( 27163657 )
2016
35
Rubella Immunity in Pregnant Native Taiwanese and Immigrants from Asian Countries. ( 27895276 )
2016
36
Is birth cohort 1985/9-1990/8 a susceptibility window for congenital rubella syndrome in Taiwan? ( 27343317 )
2016
37
Fetal and neonatal abnormalities due to congenital rubella syndrome: a review of literature. ( 27002428 )
2016
38
Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal. ( 27488930 )
2016
39
Where to Now for the Standardisation of Anti-rubella IgG Testing. ( 27170018 )
2016
40
Economic impact of switching rubella IgG methodologies to the prenatal public health program in Alberta. ( 27567094 )
2016
41
Measles-Mumps-Rubella vaccine for children with egg allergy: Is admission for inpatient vaccination necessary? ( 27770112 )
2016
42
Estimating the burden of rubella virus infection and congenital rubella syndrome through a rubella immunity assessment among pregnant women in the Democratic Republic of the Congo: Potential impact on vaccination policy. ( 27866768 )
2016
43
Introduction of rubella-containing-vaccine to Madagascar: implications for roll-out and local elimination. ( 27122178 )
2016
44
Antiviral activity of hemolymph of Podalia against rubella virus. ( 27896559 )
2016
45
Immunolocalization and Distribution of Rubella Antigen in Fatal Congenital Rubella Syndrome. ( 26870820 )
2016
46
Early detection and response for measles and rubella cases through the (Nursery) School Absenteeism Surveillance System in Ibaraki Prefecture. ( 27181348 )
2016
47
Vaccination in secondary school students expedites rubella control and prevents congenital rubella syndrome. ( 27899091 )
2016
48
Laboratory confirmation of rubella infection in suspected measles cases. ( 27018071 )
2016
49
Mumps antibody in the Thai population 17 years after the universal measles mumps rubella vaccination program. ( 27482805 )
2016
50
Evaluation of impact of measles rubella campaign on vaccination coverage and routine immunization services in Bangladesh. ( 27519586 )
2016

Variations for Rubella

Expression for Rubella

Search GEO for disease gene expression data for Rubella.

Pathways for Rubella

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1
2 12.6 HLA-A HLA-B IFNA21 IFNAR2 IL4 TNF
3
Show member pathways
12.55 CALR CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1
4
Show member pathways
12.51 HLA-DPB1 HLA-DRB1 IL10RB IL4 TNF
5
Show member pathways
12.51 CD40LG HLA-DPB1 HLA-DRB1 IFNAR2 IL10RB IL4
6
Show member pathways
12.51 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1 IFNA21
7
Show member pathways
12.43 HLA-A HLA-B IFNA21 IFNAR2 IL4 TNF
8 12.42 C1QBP CD40LG IL4 TNF
9
Show member pathways
12.35 HLA-A HLA-B HLA-DPB1 HLA-DRB1 IFNA21 IFNAR2
10 12.34 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1 TNF
11
Show member pathways
12.3 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DRB1 IFNA21
12 12.24 HLA-A HLA-B HLA-DPB1 HLA-DRB1 IL10RB
13 12.17 HLA-DPB1 HLA-DRB1 IFNA21 IL10RB TNF
14
Show member pathways
12.13 IFNA21 IFNAR2 IL10RB IL4
15
Show member pathways
12.12 CD40LG HLA-DPB1 HLA-DRB1 IL10RB IL4 TNF
16 12.09 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1
17 12.05 CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1
18
Show member pathways
12.01 HLA-A HLA-B IFNA21 IFNAR2 IL4 TNF
19 11.95 CD40LG HLA-A HLA-B
20 11.93 IFNA21 IFNAR2 TNF
21
Show member pathways
11.86 HLA-A HLA-DRB1 IL4
22 11.84 HLA-DPB1 HLA-DRB1 IL4 TNF
23 11.77 IFNA21 IFNAR2 IL10RB
24 11.75 HLA-DPB1 HLA-DRB1 TNF
25
Show member pathways
11.67 CD40LG IL4 TNF
26 11.63 CD40LG IL4 TNF
27
Show member pathways
11.57 HLA-A IFNAR2 TNF
28 11.46 IL10RB IL4 TNF
29 11.22 HLA-DRB1 IL4 TNF
30 11.13 CALR HLA-A HLA-B

GO Terms for Rubella

Cellular components related to Rubella according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.95 C1QBP CALR CD40LG IFNA21 IFNAR2 IL4
2 external side of plasma membrane GO:0009897 9.65 CALR CD40LG HLA-DRB1 IL4 TNF
3 cell surface GO:0009986 9.56 C1QBP CALR CD40LG HLA-A HLA-B HLA-DPB1
4 phagocytic vesicle membrane GO:0030670 9.5 CALR HLA-A HLA-B
5 ER to Golgi transport vesicle membrane GO:0012507 9.46 HLA-A HLA-B HLA-DPB1 HLA-DRB1
6 MHC class II protein complex GO:0042613 9.43 HLA-DPB1 HLA-DRB1
7 MHC class I protein complex GO:0042612 9.37 HLA-A HLA-B
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.02 CALR HLA-A HLA-B HLA-DPB1 HLA-DRB1

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 C1QBP HLA-A HLA-B HLA-DPB1 HLA-DRB1 TRIM5
2 regulation of immune response GO:0050776 9.84 CD40LG HLA-A HLA-B IL4
3 response to virus GO:0009615 9.79 IFNAR2 TNF TRIM22
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.78 CD40LG TNF TRIM22 TRIM5
5 T cell costimulation GO:0031295 9.77 CD40LG HLA-DPB1 HLA-DRB1
6 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.75 CALR HLA-A HLA-B
7 B cell differentiation GO:0030183 9.73 CD40LG IFNA21 IL4
8 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.73 IL4 TNF TRIM22 TRIM5
9 positive regulation of T cell proliferation GO:0042102 9.72 CD40LG HLA-DPB1 IL4
10 defense response to virus GO:0051607 9.72 IFNA21 IFNAR2 IL10RB TRIM22 TRIM5
11 viral process GO:0016032 9.7 C1QBP HLA-A HLA-B HLA-DRB1 MOG TRIM22
12 type I interferon signaling pathway GO:0060337 9.67 HLA-A HLA-B IFNA21 IFNAR2
13 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.63 CALR HLA-A HLA-B
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.62 CALR TNF
15 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.61 HLA-DPB1 HLA-DRB1
16 positive regulation of chemokine biosynthetic process GO:0045080 9.6 IL4 TNF
17 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.58 HLA-A HLA-B
18 positive regulation of dendritic cell chemotaxis GO:2000510 9.57 C1QBP CALR
19 antigen processing and presentation GO:0019882 9.56 HLA-A HLA-B HLA-DPB1 HLA-DRB1
20 protection from natural killer cell mediated cytotoxicity GO:0042270 9.52 HLA-A HLA-B
21 regulation of immunoglobulin secretion GO:0051023 9.51 CD40LG TNF
22 positive regulation of mononuclear cell migration GO:0071677 9.49 IL4 TNF
23 interferon-gamma-mediated signaling pathway GO:0060333 9.43 HLA-A HLA-B HLA-DPB1 HLA-DRB1 TRIM22 TRIM5
24 immune response GO:0006955 9.32 C1QBP CD40LG HLA-A HLA-B HLA-DPB1 HLA-DRB1

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 CD40LG IFNA21 IL4 TNF
2 complement component C1q binding GO:0001849 9.16 C1QBP CALR
3 peptide antigen binding GO:0042605 8.92 HLA-A HLA-B HLA-DPB1 HLA-DRB1

Sources for Rubella

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....